uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

[1]  G. Rottinghaus,et al.  Celecoxib concentration predicts decrease in prostaglandin E2 concentrations in nipple aspirate fluid from high risk women , 2008, BMC Cancer.

[2]  F. Castellino,et al.  A urokinase‐type plasminogen activator deficiency diminishes the frequency of intestinal adenomas in ApcMin/+ mice , 2007, The Journal of pathology.

[3]  Chun‐Hsiung Huang,et al.  Cyclooxygenase-2 inhibitor ameliorates ureteric damage in rats with obstructed uropathy. , 2007, European journal of pharmacology.

[4]  S. Goldman,et al.  Angiogenic inhibition reduces germinal matrix hemorrhage , 2007, Nature Medicine.

[5]  E. Sauter,et al.  Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer , 2006, BMC Cancer.

[6]  V. Sukhatme,et al.  Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. , 2006, Journal of the National Cancer Institute.

[7]  J. Kucab,et al.  Celecoxib Inhibits Urokinase-Type Plasminogen Activator (uPA) Production in MDA-MB-231 Breast Cancer Cells , 2005, Breast Cancer Research and Treatment.

[8]  G. Basu,et al.  Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. , 2004, Molecular cancer research : MCR.

[9]  I. Russo,et al.  The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  W. Folk,et al.  Association of uPA, PAI‐1, and uPAR in Nipple Aspirate Fluid (NAF) with Breast Cancer , 2003, Cancer journal.

[11]  V. Sukhatme,et al.  In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril. , 2003, Journal of the National Cancer Institute.

[12]  M. Duffy.  Urokinase Plasminogen Activator and Its Inhibitor, Pai-1, as Prognostic Markers in Breast Cancer: from Pilot to Level 1 Evidence Studies , 2002 .

[13]  U. Hofmann,et al.  Simple and sensitive method for the determination of celecoxib in human serum by high-performance liquid chromatography with fluorescence detection. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[14]  M. Jo,et al.  Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. , 2001, Journal of cell science.

[15]  P. Chappuis,et al.  Functional evaluation of plasmin formation in primary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Nils Brünner,et al.  The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin , 2001, The Journal of cell biology.

[17]  F. Blasi.  Proteolysis, Cell Adhesion, Chemotaxis, and Invasiveness Are Regulated by the u-PA-u-PAR-PAI-1 System , 1999, Thrombosis and Haemostasis.

[18]  M. Skobe,et al.  Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization , 1998, Nature Medicine.

[19]  M. Duffy,et al.  The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.

[20]  E. Diamandis,et al.  Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  M. Duffy,et al.  Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer , 1994, Cancer.

[22]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[23]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[24]  D. Belin,et al.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase , 1985, The Journal of cell biology.

[25]  P. Engstrom,et al.  Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. , 1997, British Journal of Cancer.